What could possibly go wrong? It’s growth-oriented, with steadily increasing sales, and operates in the obesity management space. It would only become a bad investment if widespread poverty from an economic depression became the default method of weight control.
Its main vulnerability is an overreliance on obesity treatments, but the company is actively working on diversifying its portfolio. Overall, a strong buy at a lower price point.